Annual report pursuant to Section 13 and 15(d)

BUSINESS (Details Narrative)

v3.24.1
BUSINESS (Details Narrative)
Jul. 28, 2016
BioCorRx Pharmaceuticals, Inc [Member]  
Management fee 24.20%
Series A Convertible Preferred Stock [Member]  
Equity issued ownership 75.80%